Evotec Adjusts 2026 Financial Outlook Amid Strategic Partnership Delays

Evotec SE has released its preliminary financial results for the first half of 2026, highlighting group revenues of €300.1 million and an adjusted Group EBITDA of -€42.7 million. The company anticipates full-year revenues of €570 to 610 million, a significant reduction from its previous forecast due to delays in milestone achievements with partners.

The revised outlook attributes 40% of the revenue shortfall to deferred revenue recognition pushed to 2027 and 45% to ongoing negotiations in strategic partnerships. The company's base business shows resilience, with D&PD net sales increasing by 28% year-on-year, indicating improved customer engagement.

Despite short-term challenges, Evotec continues to focus on operational excellence and has maintained its target of achieving 20-30% cost savings by the end of 2027. The company remains engaged in high-level discussions for new programs in crucial therapeutic areas.